... and (3) actually reporting the AE for the comparator product directly to FDA. As standard practice in pharmacovigilance, ...

... chlorhexidine and neomycin cream (Naseptin), octenisan and other products Comparator: Different timing of nasal decolonisation compared to each ... chlorhexidine and neomycin cream (Naseptin), octenisan and other products) in combination with body wash using alternative interventions such as: ... nasal decolonisation protocols Outcomes: ...

... interventions above were classed as cannabis-based medicinal products. Eligibility criteria – comparator Placebo Outcomes Participant reported pain relief of 30% ...

... above will be classed as cannabis-based medicinal products. Eligibility criteria – comparator Placebo Any relevant treatment Combination of treatments Usual ...

... above will be classed as cannabis-based medicinal products. Eligibility criteria – comparator Placebo Any relevant antiemetic treatment Combination of treatments ...

... as a proportion of the difference between active comparator and placebo. Such ideas were formulated with the aim of ensuring that the test product was superior to . . . placebo.” 9 Systematic reviewers may ...

... standard oral anti-spasticity medications. Methods Population, interventions/comparators and outcomes The objective of this analysis is to develop a de novo economic model to estimate the cost-effectiveness of the cannabis-derived medicinal products as a treatment option for spasticity. The target ...

... category. An evaluation of applicability also considers the comparators and outcomes. In this evidence base, a wide variety of control dressings was used, and in a few of the studies, skin substitute products were actually compared with each other. When considering ...

... cost effective and is said to dominate the comparator. Another summary measure of cost effectiveness used in the presentation of results below is the net monetary benefit (NMB) which is calculated as the product of the QALYs from the intervention and the ...

... consistent with recommendations in the NICE guidance The comparator group will NOT receive ... (FFP; cryoprecipitate; platelets) Reoperation rate Mortality ( ...